<DOC>
<DOCNO>
EP-0003677
</DOCNO>
<TEXT>
<DATE>
19790822
</DATE>
<IPC-CLASSIFICATIONS>
C07D-333/20 A61K-31/513 C07D-409/12 C07D-213/55 A61K-31/495 C07D-333/00 C07D-409/00 C07D-213/00 C07D-213/85 C07D-239/00 A61P-1/14 C07D-405/00 A61P-1/00 A61P-1/04 C07D-239/56 C07D-405/12 C07D-317/00 C07D-213/61 A61P-43/00 <main>C07D-405/00</main> C07D-405/14 C07D-333/18 A61P-9/00 C07D-213/40 A61P-9/12 A61K-31/505 C07D-213/64 C07D-409/14 A61P-29/00 C07D-317/46 
</IPC-CLASSIFICATIONS>
<TITLE>
pyrimidones, processes for their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
smith kline french labgb<sep>smith kline & french laboratories limited<sep>smith kline &amp; french laboratories limitedmundellswelwyn garden city hertfordshire, al7 1eygb<sep>smith kline & french laboratories limited<sep>
</APPLICANT>
<INVENTOR>
brown thomas henry<sep>ife robert john<sep>brown, thomas henry<sep>ife, robert john<sep>brown, thomas henry115 daniellswelwyn garden city hertfordshiregb<sep>ife, robert john19 mobbsbury waystevenage hertfordshiregb<sep>brown, thomas henry<sep>ife, robert john<sep>brown, thomas henry115 daniellswelwyn garden city hertfordshiregb<sep>ife, robert john19 mobbsbury waystevenage hertfordshiregb<sep>
</INVENTOR>
<ABSTRACT>
pyrimidones which are histamine h₂-antagonists  have the structure    in which d is hydrogen or an aminoalkyl group, x is oxygen  or sulphur, y is oxygen, sulphur or methylene, n is  2 or 3, z is hydrogen or lower alkyl, a is c₁-c₅ alkylene  in which one methylene group can be replaced by oxygen  or sulphur, and b is hydrogen, methyl, c₃-c₆ cycloalkyl, or  an aryl or heteroaryl group.  
</ABSTRACT>
</TEXT>
</DOC>
